Related Experiment Video

Updated: Dec 25, 2025

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
08:04

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

12.4K

Not So FASt: Tumor Cells Resisting Death Drive CAR T-cell Dysfunction

Michael R Green1,2, Sattva S Neelapu3

  • 1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Cancer Discovery
|April 3, 2020
PubMed

Insights

Researchers found a new way tumors resist CAR T-cell therapy. Reduced death receptor genes in tumors cause resistance, CAR T-cell dysfunction, and poor patient outcomes in B-cell cancers.

Area of Science:

  • Immunology
  • Oncology
  • Genetics

Background:

  • Chimeric antigen receptor (CAR) T-cell therapy is a promising treatment for B-cell malignancies.
  • Resistance to CAR T-cell therapy remains a significant clinical challenge.
  • Understanding resistance mechanisms is crucial for improving therapeutic efficacy.

Purpose of the Study:

  • To identify novel tumor-intrinsic mechanisms of resistance to CD19-targeted CAR T-cell therapy.
  • To elucidate the role of death receptor gene expression in CAR T-cell resistance.
  • To correlate resistance mechanisms with clinical outcomes in patients with B-cell malignancies.

Main Methods:

  • Analysis of tumor samples from patients undergoing CAR T-cell therapy.
  • Assessment of gene expression, focusing on death receptor pathways.
  • Evaluation of CAR T-cell function and patient clinical data.

Main Results:

  • Reduced expression of death receptor genes in tumors was identified as a key mechanism of resistance.
  • This downregulation mediated resistance to CAR T-cell-mediated killing.
  • Progressive CAR T-cell dysfunction was observed, correlating with unfavorable clinical outcomes.

Conclusions:

  • Tumor-intrinsic downregulation of death receptor genes confers resistance to CAR T-cell therapy in B-cell malignancies.
  • This mechanism contributes to CAR T-cell dysfunction and predicts poor clinical outcomes.
  • Targeting death receptor pathways may represent a strategy to overcome resistance.

More Related Videos

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

7.3K
Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

1.3K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.8K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.3K
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
53.3K